Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 405 KB, PDF-dokument
Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.
Bidragets oversatte titel | Management of non-alcoholic fatty liver disease |
---|---|
Originalsprog | Dansk |
Artikelnummer | V04220239 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 184 |
Udgave nummer | 42 |
Antal sider | 8 |
ISSN | 0041-5782 |
Status | Udgivet - 2022 |
- Humans, Non-alcoholic Fatty Liver Disease/diagnosis, Liver Cirrhosis/complications, Biopsy, Fibrosis, Referral and Consultation, Liver/pathology
Forskningsområder
Links
- https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-10/v04220239_web.pdf
Forlagets udgivne version
ID: 326032542